2 TBARS
|
|
|
- あきとし あいきょう
- 7 years ago
- Views:
Transcription
1 1 - AsA) ) ( ODS AsA TOC ODS ODS ODS PQ
2 2 TBARS
3 3 1) 2)
4 4
5 5 ODS PQ 250mg/ PQ 125mg/ PQ 125mg/ PQ PQ 125mg/ Mg ODS Mg 25g Mg Na Ca ATP Mg ODS Mg PQ
6 6 Mg ODS Mg PQ Mg Mg
7 7 Table 1 Composition of basal diet Ingredient Amount (g/kg diet) Vitamin-free casein 250 α Starch Sucrose 300 Stripped corn oil 100 Salt mixture ( AIN-76 ) 35 Vitamin mixture ( AIN-76) * 10 Choline chloride 1.5 * α Tocopherol : 50 mg, Vitamin A 6000 IU AsA: 300mg
8 8 Experiment A : Ca, Fe ODS rat ( 6W male) Experiment B : Mn, Zn, Cu, I, Se, Cr Fed test diet ( PQ 125 mg/kg diet ) Fed basal diet Killed on fulminant toxicosis Day Fig. 1 Design of experiment 1
9 9 ODS rat ( 6W male) Experiment C : Na, K, Mg Experiment D : K, Mg Fed test diet ( PQ 125 mg/kg diet ) Fed basal diet Killed on fulminant toxicosis Day Fig. 2 Design of experiment 2
10 10 Table 2 Mineral amounts of diets in experiment A Ingredient Amount a-i a- II a- III a- IV 1 CaHPO 4 1/2 * 1 1/2 1 2 NaCl 1/2 1/2 1/2 1 3 K 3 C 6 H 5 O 7 1/2 1/2 1/2 1 4 K 2 SO 4 1/2 1/2 1/2 1 5 MgO 1/2 1/2 1/2 1 6 MnCO 3 1/2 1/2 1/2 1 7 FeSO 4 1/2 1/2 * ZnO 1/2 1/2 1/2 1 9 CuO 1/2 1/2 1/ KIO3 1/2 1/2 1/ Na 2 SeO 3 1/2 1/2 1/ CrK( SO 4 ) 2 1/2 1/2 1/2 1
11 11 Table 3 Mineral amounts of diets in experiment B Ingredient Amount b-i b-ii b-iii 1 CaHPO 4 1/ NaCl 1/ K 3 C 6 H 5 O 7 1/ K 2 SO 4 1/ MgO 1/ MnCO 3 1/2 1 * 1/2 7 FeSO 4 1/2 1 * 1/2 8 ZnO 1/2 1 * 1/2 9 CuO 1/2 1 * 1/2 10 KIO3 1/2 * 1/2 *1/2 11 Na 2 SeO 3 1/2 * 1/2 * 1/2 12 CrK( SO 4 ) 2 1/2 * 1/2 * 1/2
12 12 Table 4 Mineral amounts of diets in experiment C Ingredient Amount c- I c- II c- III c- IV 1 CaHPO NaCl 1 * 1/2 * 1/2 1 3 K 3 C 6 H 5 O *1/2 1 4 K 2 SO *1/2 1 5 MgO *1/2 6 MnCO 3 1/2 1/2 1/2 1/2 7 FeSO 4 1/2 1/2 1/2 1/2 8 ZnO 1/2 1/2 1/2 1/2 9 CuO 1/2 1/2 1/2 1/2 10 KIO3 1/2 1/2 1/2 1/2 11 Na 2 SeO 3 1/2 1/2 1/2 1/2 12 CrK( SO 4 ) 2 1/2 1/2 1/2 1/2
13 13 Table 5 Mineral amounts of diets in experiment D Ingredient Amount d-i d-ii d-iii 1 CaHPO NaCl K 3 C 6 H 5 O *1/2 4 K 2 SO *1/2 5 MgO 1 * 1/2 *1/2 6 MnCO 3 1/2 1/2 1/2 7 FeSO 4 1/2 1/2 1/2 8 ZnO 1/2 1/2 1/2 9 CuO 1/2 1/2 1/2 10 KIO3 1/2 1/2 1/2 11 Na 2 SeO 3 1/2 1/2 1/2 12 CrK( SO 4 ) 2 1/2 1/2 1/2
14 14 Sample add 19 volumes of cold 1.15 % KCl homogenize for 20 S with polytron homogenizer Homogenate ( 0.5 ml ) add 3 ml of 1 % phosphoric acid and 1 ml of 0.67% TBA mix heat for 45 min in boiling water bath cool to 5 C add 4 ml of n-butanol shake vigorously for 10 min centrifuge at 3000 rpm for 10 min Supernatant Colorimetric determination measure OD at 535 nm nm Fig. 3 Procedure for determination of TBARS
15 15 Sample add 19 volumes of 0.9 % NaCl homogenize for 20 S with polytron homogenizer Homogenate place 5 ml of homogenate on stainless vessel for photon count incubate at 37 C for 30 S Photon count record every 30 S for 3 min Fig.4 Procedure for determination of chemiluminescence Photon counting apparatus Hamamatsu photonics : Model R-1333 photomultiplier Model C-1230 photon counter Model C-2761 thermoelectric cooler
16 16 Number of toxicosis rats a-i : Mineral 1/2 a-ii : Mineral 1/2 except Ca 2+ a-iii : : Mineral 1/2 1/2 except Fe Fe a-iv IV : : Mineral Fig. 5 Day on Fulminant toxicosis expresion of ODS rats fed PQ in experiment A
17 17 Table 6 Body weight and organs weight of ODS rats fed PQ in experiment A Organs Groups a- I a-ii a- III a- IV Body weight ± ± ± ± 21.2 Kidney 1.69 ± ± ± ± 0.04 Lung 0.59 ± ± ± ± 0.05 Liver 3.59 ± ± ± ± 0.21 Heart 0.44 ± ± ± ± 0.01 Spleen 0.18 ± ± ± ± 0.01 Testis 1.54 ± ± ± ± 0.12 a-i : Mineral 1/2, ; Vitamin 1/2, a-ii : Mineral 1/2, + Ca ; Vitamin 1/2 a-iii : Mineral 1/2, + Fe ; Vitamin 1/2 a-iv : Mineral, 1 ; Vitamin 1/2 Organs weight : g/100g body weight, values : means ± SD
18 18 Table 7 Body weight and organs weight of ODS rats fed PQ in experiment B Organs Groups b-i b-ii b-iii Body weight ± ± ± 13.1 Kidney 1.61 ± ± ± 0.05 Lung 0.54 ± ± ± 0.02 Liver 3.80 ± ± ± 0.33 Heart 0.44 ± ± ± 0.02 Spleen 0.16 ± ± ± 0.01 Testis 1.36 ± ± ± 0.13 b-i : Mineral 1/2 ; Vitamin 1/2 b-ii : Mineral ( I, Se, Cr ) 1/2 ; Vitamin 1/2 b-iii : Mineral ( I, Se, Cr, Mn, Fe, Zn, Cu ) 1/2 ; Vitamin 1/2 Organs weight : g/100g body weight, values : means ± SD
19 19 Table 8 Body weight and organs weight of ODS rats fed PQ in experiment C Organs Groups c- I c- II c- III c-iv Body weight ± ± ± ± 14.1 Kidney 1.00 ± ± ± ± 0.15 Lung 0.48 ± ± ± ± 0.04 Liver 4.47 ± ± ± ± 0.55 Heart 0.36 ± ± ± ± 0.02 Spleen 0.22 ± ± ± ± 0.02 Testis 1.24 ± ± ± ± 0.08 c-i : Mineral ( Ca, Na, K, Mg ) 1 c- II : Mineral ( Ca, K, Mg ) 1, Na 1/2 c-iii : Mineral ( Ca, Mg ) 1, ( Na, K ) 1/2 c-iv : Mineral ( Ca, Na, K ) 1, Mg 1/2 c- I - c- IV : Mineral ( Mn, Fe, Zn, Cu, I, Se, Cr ) 1/2, Vitamin 1/2 Organs weight : g/100g body weight, values : means ± SD
20 20 Table 9 Body weight and organs weight of ODS rats fed PQ in experiment D Organs Groups d- I d-ii d-iii Body weight ± ± ± 6.5 Kidney 1.00 ± ± ± 0.12 Lung 0.50 ± ± ± 0.02 Liver 4.66 ± ± ± 0.33 Heart 0.37 ± ± ± 0.02 Spleen 0.22 ± ± ± 0.02 Testis 1.23 ± ± ± 0.04 d- I : Mineral ( Ca, Na, K, Mg ) 1 d-ii : Mineral ( Ca, Na, K ) 1, Mg 1/2 d-iii : Mineral ( Ca, Na ) 1, ( K, Mg ) 1/2 d-i - d-iii : Mineral ( Mn, Fe, Zn, Cu, I, Se, Cr ) 1/2, Vitamin 1/2 Organs weight : g/100g body weight, values : means ± SD
21 21 Table 9 Body weight and organs weight of ODS rats fed PQ in experiment D Organs Groups d- I d-ii d-iii Body weight ± ± ± 6.5 Kidney 1.00 ± ± ± 0.12 Lung 0.50 ± ± ± 0.02 Liver 4.66 ± ± ± 0.33 Heart 0.37 ± ± ± 0.02 Spleen 0.22 ± ± ± 0.02 Testis 1.23 ± ± ± 0.04 d- I : Mineral ( Ca, Na, K, Mg ) 1 d-ii : Mineral ( Ca, Na, K ) 1, Mg 1/2 d-iii : Mineral ( Ca, Na ) 1, ( K, Mg ) 1/2 d-i - d-iii : Mineral ( Mn, Fe, Zn, Cu, I, Se, Cr ) 1/2, Vitamin 1/2 Organs weight : g/100g body weight, values : means ± SD
22 22 b-i Experiment groups b-ii b-iii TBARS ( MDA nmoles / g tissue ) Fig.7 TBARS values in liver of ODS rat in experiment B b-i : Mineral 1/2 ; Vitamin 1/2 b-ii : Mineral ( I, Se, Cr ) 1/2 ; Vitamin 1/2 b-iii : Mineral ( I, Se, Cr, Mn, Fe, Zn, Cu ) 1/2 ; Vitamin 1/2,
23 23 Experiment groups c-i c-ii c-iii c-iv TBARS ( MDA nmoles / g tissue ) Fig. 8 TBARS values in liver of ODS rat in experiment C c-i : Mineral ( Ca, Na, K, Mg ) 1 c- II : Mineral ( Ca, K, Mg ) 1, Na 1/2 c-iii : Mineral ( Ca, Mg ) 1, ( Na, K ) 1/2 c-iv : Mineral ( Ca, Na, K ) 1, Mg 1/2
24 24 Experiment groups d-i d-ii d-iii TBARS ( MDA nmoles / g tissue ) Fig.9 TBARS values in liver of ODS rat in experiment D d-i : Mineral ( Ca, Na, K, Mg ) 1, d-ii : Mineral ( Ca, Na, K ) 1, Mg 1/2 d-iii : Mineral ( Ca, Na ) 1, ( K, Mg ) 1/2
25 25 a-i Experiment groups a-ii a-iii a-iv Fig Chemiliminescence ( c/s/g tissue ) Chemiluminescence in liver of ODS rat in experiment A a-i : Mineral 1/2, Vitamin 1/2 a-ii : Mineral 1/2, + Ca, Vitamin 1/2 a-ii : Mineral 1/2, +Fe, Vitamin 1/2 a-iv : Mineral 1, Vitamin 1/2
26 26 b-i Experiment groups b-ii b-iii Fig Chemiluminescence ( c/s/g tissue ) Chemiluminescence in liver of ODS rat in experiment B b-i : Mineral 1/2 ; Vitamin 1/2 b-ii : Mineral ( I, Se, Cr ) 1/2 ; Vitamin 1/2 b-iii : Mineral ( I, Se, Cr, Mn, Fe, Zn, Cu ) 1/2 ; Vitamin 1/2
27 27 c-i Experiment groups c-ii c-iii c-iv Fig Chemiluminescence ( c/s/g tissue ) Chemiluminescence in liver of ODS rat in experiment C c-i : Mineral (Ca, Na, K, Mg ) 1 c- II : Mineral (Ca, K, Mg ) 1, Na 1/2 c-iii : Mineral (Ca, Mg ) 1, ( Na, K ) 1/2 c- VI : Mineral (Ca, Na, K ) 1, Mg 1/2
28 28 c-i Experimental groups c-ii c-iii Fig Chemiluminescence ( c/s/g tissue ) Chemiluminescence in liver of ODS rat in experiment D : Mineral ( Ca, Na, K, Mg ) 1 d-ii : Mineral ( Ca, Na, K ) 1, Mg 1/2 d-iii : Mineral ( Ca, Na ) 1, ( K, Mg ) 1/2
i
14 i ii iii iv v vi 14 13 86 13 12 28 14 16 14 15 31 (1) 13 12 28 20 (2) (3) 2 (4) (5) 14 14 50 48 3 11 11 22 14 15 10 14 20 21 20 (1) 14 (2) 14 4 (3) (4) (5) 12 12 (6) 14 15 5 6 7 8 9 10 7
取扱説明書 ［F-05E］
F-05E 12.11 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 a b 22 c d e 23 24 a o c d a b p q b o r s e f h i j k l m g f n a b c d e f g h 25 i j k l m n o p q r s a X b SD 26 27 28 X 29 a b c
温泉の化学 １
H O 1,003 516 149 124 2,237 1974 90 110 1km 2,400 ( 100 Mg 200 (98 ) 43,665 mg 38,695 mg 19,000 mg 2000 2000 Na-Ca-Cl 806 1970 1989 10 1991 4 ph 1 981 10,000 1993... (^^; (SO_4^{2-}) " " 1973-1987 1970
2 Zn Zn + MnO 2 () 2 O 2 2 H2 O + O 2 O 2 MnO 2 2 KClO 3 2 KCl + 3 O 2 O 3 or 3 O 2 2 O 3 N 2 () NH 4 NO 2 2 O + N 2 ( ) MnO HCl Mn O + CaCl(ClO
1 [1]. Zn + 2 H + Zn 2+,. K Ca Na Mg Al Zn Fe Ni Sn Pb H Cu Hg Ag Pt Au H (H + ),,. [2] ( ) ( ) CO 2, S, SO 2, NH 3 () + () () + () FeS Fe S ( ) + ( ) ( ) + ( ) 2 NH 4 Cl + Ca(OH) 2 Ca O + 2 NH 3,.,,.,,.,.
i ii iii iv v vi vii ( ー ー ) ( ) ( ) ( ) ( ) ー ( ) ( ) ー ー ( ) ( ) ( ) ( ) ( ) 13 202 24122783 3622316 (1) (2) (3) (4) 2483 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) 11 11 2483 13
Nutritional Value of S-Methylcysteine Sulfoxide (Methiin) (V) Investigations on effects of S-Methylcysteine Sulfoxide on Methionine-substitution and a
Nutritional Value of S-Methylcysteine Sulfoxide (Methiin) (V) Investigations on effects of S-Methylcysteine Sulfoxide on Methionine-substitution and amino acid imbalance. Noriko Yagi, Machiko Takashima
44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2)
(1) I 44 II 45 III 47 IV 52 44 4 I (1) ( ) 1945 8 9 (10 15 ) ( 17 ) ( 3 1 ) (2) 45 II 1 (3) 511 ( 451 1 ) ( ) 365 1 2 512 1 2 365 1 2 363 2 ( ) 3 ( ) ( 451 2 ( 314 1 ) ( 339 1 4 ) 337 2 3 ) 363 (4) 46
i ii i iii iv 1 3 3 10 14 17 17 18 22 23 28 29 31 36 37 39 40 43 48 59 70 75 75 77 90 95 102 107 109 110 118 125 128 130 132 134 48 43 43 51 52 61 61 64 62 124 70 58 3 10 17 29 78 82 85 102 95 109 iii
262014 3 1 1 6 3 2 198810 2/ 198810 2 1 3 4 http://www.pref.hiroshima.lg.jp/site/monjokan/ 1... 1... 1... 2... 2... 4... 5... 9... 9... 10... 10... 10... 10... 13 2... 13 3... 15... 15... 15... 16 4...
178 5 I 1 ( ) ( ) 10 3 13 3 1 8891 8 3023 6317 ( 10 1914 7152 ) 16 5 1 ( ) 6 13 3 13 3 8575 3896 8 1715 779 6 (1) 2 7 4 ( 2 ) 13 11 26 12 21 14 11 21
I 178 II 180 III ( ) 181 IV 183 V 185 VI 186 178 5 I 1 ( ) ( ) 10 3 13 3 1 8891 8 3023 6317 ( 10 1914 7152 ) 16 5 1 ( ) 6 13 3 13 3 8575 3896 8 1715 779 6 (1) 2 7 4 ( 2 ) 13 11 26 12 21 14 11 21 4 10 (
JAJP
Agilent 7500ce ORS ICP-MS Glenn Woods Agilent Technologies Ltd. 5500 Lakeside, Cheadle Royal Business Park Stockport UK Agilent 7500ce ICP-MS 5 7500ce (ORS) 1 ORS 7500ce ORS ICP-MS ( ) 7500 ICP-MS (27.12
untitled
NPO 2006( ) 11 14 ( ) (2006/12/3) 1 50% % - - (CO+H2) ( ) 6 44 1) --- 2) ( CO H2 ) 2 3 3 90 3 3 2 3 2004 ( ) 1 1 4 1 20% 5 ( ) ( ) 2 6 MAWERA ) MAWERA ( ) ( ) 7 6MW -- 175kW 8 ( ) 900 10 2 2 2 9 -- - 10
untitled
i ii iii iv v 43 43 vi 43 vii T+1 T+2 1 viii 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 a) ( ) b) ( ) 51
AccessflÌfl—−ÇŠš1
ACCESS ACCESS i ii ACCESS iii iv ACCESS v vi ACCESS CONTENTS ACCESS CONTENTS ACCESS 1 ACCESS 1 2 ACCESS 3 1 4 ACCESS 5 1 6 ACCESS 7 1 8 9 ACCESS 10 1 ACCESS 11 1 12 ACCESS 13 1 14 ACCESS 15 1 v 16 ACCESS
2
1 2 3 4 5 6 7 8 9 10 I II III 11 IV 12 V 13 VI VII 14 VIII. 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 _ 33 _ 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 VII 51 52 53 54 55 56 57 58 59
4 1 Ampère 4 2 Ampere 31
4. 2 2 Coulomb 2 2 2 ( ) electricity 2 30 4 1 Ampère 4 2 Ampere 31 NS 2 Fleming 4 3 B I r 4 1 0 1.257 10-2 Gm/A µ 0I B = 2πr 4 1 32 4 4 A A A A 4 4 10 9 1 2 12 13 14 4 1 16 4 1 CH 2 =CH 2 28.0313 28 2
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 () - 1 - - 2 - - 3 - - 4 - - 5 - 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57
- - - - - - - - - - - - - - - - - - - - - - - - - -1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -2...2...3...4...4...4...5...6...7...8...
取 扱 説 明 書 - - - - - - - - - - - - - - - - - - - - - - - - - -1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -2...2...3...4...4...4...5...6...7...8...9...11 - - - - - - - - - - - - - - - - -
86 7 I ( 13 ) II ( )
10 I 86 II 86 III 89 IV 92 V 2001 93 VI 95 86 7 I 2001 6 12 10 2001 ( 13 ) 10 66 2000 2001 4 100 1 3000 II 1988 1990 1991 ( ) 500 1994 2 87 1 1994 2 1000 1000 1000 2 1994 12 21 1000 700 5 800 ( 97 ) 1000
入門ガイド
ii iii iv NEC Corporation 1998 v P A R 1 P A R 2 P A R 3 T T T vi P A R T 4 P A R T 5 P A R T 6 P A R T 7 vii 1P A R T 1 2 2 1 3 1 4 1 1 5 2 3 6 4 1 7 1 2 3 8 1 1 2 3 9 1 2 10 1 1 2 11 3 12 1 2 1 3 4 13
<4D6963726F736F667420506F776572506F696E74202D208376838C835B83938365815B835683878393312E707074205B8CDD8AB78382815B83685D>
i i vi ii iii iv v vi vii viii ix 2 3 4 5 6 7 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
SC-85X2取説
I II III IV V VI .................. VII VIII IX X 1-1 1-2 1-3 1-4 ( ) 1-5 1-6 2-1 2-2 3-1 3-2 3-3 8 3-4 3-5 3-6 3-7 ) ) - - 3-8 3-9 4-1 4-2 4-3 4-4 4-5 4-6 5-1 5-2 5-3 5-4 5-5 5-6 5-7 5-8 5-9 5-10 5-11
第１部 一般的コメント
(( 2000 11 24 2003 12 31 3122 94 2332 508 26 a () () i ii iii iv (i) (ii) (i) (ii) (iii) (iv) (a) (b)(c)(d) a) / (i) (ii) (iii) (iv) 1996 7 1996 12
表1票4.qx4
iii iv v 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 22 23 10 11 24 25 26 27 10 56 28 11 29 30 12 13 14 15 16 17 18 19 2010 2111 22 23 2412 2513 14 31 17 32 18 33 19 34 20 35 21 36 24 37 25 38 2614
untitled
23 12 10 12:55 ~ 18:45 KKR Tel0557-85-2000 FAX0557-85-6604 12:55~13:00 13:00~13:38 I 1) 13:00~13:12 2) 13:13~13:25 3) 13:26~13:38 13:39~14:17 II 4) 13:39~13:51 5) 13:52 ~ 14:04 6) 14:05 ~ 14:17 14:18 ~
第１章 国民年金における無年金
1 2 3 4 ILO ILO 5 i ii 6 7 8 9 10 ( ) 3 2 ( ) 3 2 2 2 11 20 60 12 1 2 3 4 5 6 7 8 9 10 11 12 13 13 14 15 16 17 14 15 8 16 2003 1 17 18 iii 19 iv 20 21 22 23 24 25 ,,, 26 27 28 29 30 (1) (2) (3) 31 1 20
36 th IChO : - 3 ( ) , G O O D L U C K final 1
36 th ICh - - 5 - - : - 3 ( ) - 169 - -, - - - - - - - G D L U C K final 1 1 1.01 2 e 4.00 3 Li 6.94 4 Be 9.01 5 B 10.81 6 C 12.01 7 N 14.01 8 16.00 9 F 19.00 10 Ne 20.18 11 Na 22.99 12 Mg 24.31 Periodic
o 2o 3o 3 1. I o 3. 1o 2o 31. I 3o PDF Adobe Reader 4o 2 1o I 2o 3o 4o 5o 6o 7o 2197/ o 1o 1 1o
78 2 78... 2 22201011... 4... 9... 7... 29 1 1214 2 7 1 8 2 2 3 1 2 1o 2o 3o 3 1. I 1124 4o 3. 1o 2o 31. I 3o PDF Adobe Reader 4o 2 1o 72 1. I 2o 3o 4o 5o 6o 7o 2197/6 9. 9 8o 1o 1 1o 2o / 3o 4o 5o 6o
ステンレス鋼用高性能冷間鍛造油の開発
Development of High Performance Cold Forging Oil for Stainless Steel Toshihide Ohmori, Kazuhiko Kitamura ClP ( ) Cl P-Zn ( P ) ClP-Zn High performance cold forging oil for stainless steel has been developed
20 15 14.6 15.3 14.9 15.7 16.0 15.7 13.4 14.5 13.7 14.2 10 10 13 16 19 22 1 70,000 60,000 50,000 40,000 30,000 20,000 10,000 0 2,500 59,862 56,384 2,000 42,662 44,211 40,639 37,323 1,500 33,408 34,472
- 2 -
- 2 - - 3 - (1) (2) (3) (1) - 4 - ~ - 5 - (2) - 6 - (1) (1) - 7 - - 8 - (i) (ii) (iii) (ii) (iii) (ii) 10 - 9 - (3) - 10 - (3) - 11 - - 12 - (1) - 13 - - 14 - (2) - 15 - - 16 - (3) - 17 - - 18 - (4) -
2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4 4 4 2 5 5 2 4 4 4 0 3 3 0 9 10 10 9 1 1
1 1979 6 24 3 4 4 4 4 3 4 4 2 3 4 4 6 0 0 6 2 4 4 4 3 0 0 3 3 3 4 3 2 4 3? 4 3 4 3 4 4 4 4 3 3 4 4 4 4 2 1 1 2 15 4 4 15 0 1 2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4
I? 3 1 3 1.1?................................. 3 1.2?............................... 3 1.3!................................... 3 2 4 2.1........................................ 4 2.2.......................................
1 (1) (2)
1 2 (1) (2) (3) 3-78 - 1 (1) (2) - 79 - i) ii) iii) (3) (4) (5) (6) - 80 - (7) (8) (9) (10) 2 (1) (2) (3) (4) i) - 81 - ii) (a) (b) 3 (1) (2) - 82 - - 83 - - 84 - - 85 - - 86 - (1) (2) (3) (4) (5) (6)
I
I II 1 2 3 4 5 6 7 8 9 10 11 Rp.1) 50mg 3 3 14 Rp.2) 2.5mg 2 14 Rp.1) 2.5mg 3 2 2:1 14 Rp.) 15g 1 3 28 Rp.2) 50 600mg 1 2 28 12 Rp.1) CR 20mg 1 1 1 14 Rp.2) R 200 1 2 14 Rp.3) 3 1 3 14 Rp.1) 2.5mg 0.4
これわかWord2010_第1部_100710.indd
i 1 1 2 3 6 6 7 8 10 10 11 12 12 12 13 2 15 15 16 17 17 18 19 20 20 21 ii CONTENTS 25 26 26 28 28 29 30 30 31 32 35 35 35 36 37 40 42 44 44 45 46 49 50 50 51 iii 52 52 52 53 55 56 56 57 58 58 60 60 iv
パワポカバー入稿用.indd
i 1 1 2 2 3 3 4 4 4 5 7 8 8 9 9 10 11 13 14 15 16 17 19 ii CONTENTS 2 21 21 22 25 26 32 37 38 39 39 41 41 43 43 43 44 45 46 47 47 49 52 54 56 56 iii 57 59 62 64 64 66 67 68 71 72 72 73 74 74 77 79 81 84
これでわかるAccess2010
i 1 1 1 2 2 2 3 4 4 5 6 7 7 9 10 11 12 13 14 15 17 ii CONTENTS 2 19 19 20 23 24 25 25 26 29 29 31 31 33 35 36 36 39 39 41 44 45 46 48 iii 50 50 52 54 55 57 57 59 61 63 64 66 66 67 70 70 73 74 74 77 77
provider_020524_2.PDF
1 1 1 2 2 3 (1) 3 (2) 4 (3) 6 7 7 (1) 8 (2) 21 26 27 27 27 28 31 32 32 36 1 1 2 2 (1) 3 3 4 45 (2) 6 7 5 (3) 6 7 8 (1) ii iii iv 8 * 9 10 11 9 12 10 13 14 15 11 16 17 12 13 18 19 20 (2) 14 21 22 23 24
Microsoft Word - 目次注意事項2.doc
I II 2009 1. 2. 12 50 3. 1. 2. 3 ( 0.1g, 0.01g, 0.001g ) 3. 4. 1. 2. ()A4 3. 000005 19 5 11 () 19 5 15 () EDTA " # $ 1000 500 =... mol/l Web 1) p.159 2) 1987pp.14-15 3) 1989pp.58-60 4) http://www.chem.zenkyo.h.kyoto-u.ac.jp/operation/
untitled
26 3 31 BDF BDF BDF FAME BDF BDF BDF BDF BDF BDF BDF BDF BDF FAME BDF BDF 80.0 97.0% BDF 120 330 0.8% 2.2% 1. 1 1-1 1 1-2 1 2. 2 2-1 2 2-2 5 2-3 6 3. BDF 7 3-1 7 3-2 7 3-3 14 3-4 JOY 21 3-5 32 3-6 39 3-7
平成18年版 男女共同参画白書
i ii iii iv v vi vii viii ix 3 4 5 6 7 8 9 Column 10 11 12 13 14 15 Column 16 17 18 19 20 21 22 23 24 25 26 Column 27 28 29 30 Column 31 32 33 34 35 36 Column 37 Column 38 39 40 Column 41 42 43 44 45
「産業上利用することができる発明」の審査の運用指針（案）
1 1.... 2 1.1... 2 2.... 4 2.1... 4 3.... 6 4.... 6 1 1 29 1 29 1 1 1. 2 1 1.1 (1) (2) (3) 1 (4) 2 4 1 2 2 3 4 31 12 5 7 2.2 (5) ( a ) ( b ) 1 3 2 ( c ) (6) 2. 2.1 2.1 (1) 4 ( i ) ( ii ) ( iii ) ( iv)
ÿþ
I O 01 II O III IV 02 II O 03 II O III IV III IV 04 II O III IV III IV 05 II O III IV 06 III O 07 III O 08 III 09 O III O 10 IV O 11 IV O 12 V O 13 V O 14 V O 15 O ( - ) ( - ) 16 本 校 志 望 の 理 由 入 学 後 の
48 13 13 13 38 21 13 3 13 3.1 l l l l l l 4.1.1 5mm 0.5mm 5mm 10 500mL 500mL 500mL 20 1 200 / 4 5 6 3000G 20 G1118 R N 2 10-8 GG Rcm Nrpm 1μm 2 3000G 1 /1 4.1.2PCB PCB 5mm 0.5mm 5mm 10 500mL 500mL 500mL
II II,,,, AII BII CII
2012 Course Design of 2nd Semester (2012 9 24 ) 2012 1 II........................... 3 II,,,,.... 4 2 AII........................... 5 BII.......................... 6 CII.......................... 7 CIII...........................
< B C957491E48E86312E696E6464>
10 DDS New York Academy Renal Biochemistry (Elsevier) Glutathione (John Wiley & Sons) Antioxidants in Therapy and Preventive Medicine (Plenum) The Liver: Biology and Pathophysiology (Raven Press) NO SSC
000..\..
Bull. Nagoya Univ. Museum No. 20, 79 91, 2004 Quantitative chemical analysis of rocks with X-ray fluorescence analyzer XRF-1800 NAKAZAKI Mineko TSUBOI Motohiro KANAGAWA Kazuyo KATO Takenori SUZUKI Kazuhiro
エクセルカバー入稿用.indd
i 1 1 2 3 5 5 6 7 7 8 9 9 10 11 11 11 12 2 13 13 14 15 15 16 17 17 ii CONTENTS 18 18 21 22 22 24 25 26 27 27 28 29 30 31 32 36 37 40 40 42 43 44 44 46 47 48 iii 48 50 51 52 54 55 59 61 62 64 65 66 67 68
Taro9-医薬品目次２０１２－１.PDF
5 0.1% 11 250mg 10 20mg 10 5ml 19 0.05% 13 1.25mg 10 1%5ml 19 10mg 10 0.2%100ml 18 25%50ml 9 2mg 17 5%250ml 9 20%25g 20 500 g 11 4 10g 20 Cap150mg 1 200mg 0 Cap90mg 5 20mg 10 10% 5 18 10mg 10 3%30g 20
1-1 - 2 3-2 - - 3 - i - 4 - ii - 5 - c - 6 - 4 1-7 - 2 1-8 - 2-9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - 3-18 - - 19 - - 20 - - 21 - - 22 - - 23 - iii i - 24 - - 25 - - 26 - 4-27 - 5
第2章 有機物汚濁指標の概要と問題点
3 COD Mn 3-1 3-1-1 OC 2 3 OC Oxygen Consumed 3-1 13 DO BOD OC 1 1970 OC KMnO 4 2 K 2 Cr 2 O 7 2 OC ph OC 50 OC JIS K0102 100 30 KMnO 4 3-1 COD 17 3-1 1973 1 KMnO 4 KMnO 4 COD Mn COD Mn COD COD Mn Cr COD
Microsoft Word - 高橋＿国試講習会2006m.doc
2006 19 150 20 200 19 80 2 70 1 45 1 1 30 20 105 2 40 1 1 31 95 2 25 1 1 32 1. 2. 3. 4. 5. 1 [] 25 12.5% 2006/3 6 2 1 2 3 7 A a b c d 11 e B a b c d C a b c D a b E a b c d 2 15 16 17 18 19 20 2001 2002
ii iii iv CON T E N T S iii iv v Chapter1 Chapter2 Chapter 1 002 1.1 004 1.2 004 1.2.1 007 1.2.2 009 1.3 009 1.3.1 010 1.3.2 012 1.4 012 1.4.1 014 1.4.2 015 1.5 Chapter3 Chapter4 Chapter5 Chapter6 Chapter7
1... 1... 1... 3 2... 4... 4... 4... 4... 4... 6... 10... 11... 15... 30
1 2420128 1 6 3 2 199103 189/1 1991031891 3 4 5 JISJIS X 0208, 1997 1 http://www.pref.hiroshima.lg.jp/site/monjokan/ 1... 1... 1... 3 2... 4... 4... 4... 4... 4... 6... 10... 11... 15... 30 1 3 5 7 6 7
n 2 + π2 6 x [10 n x] x = lim n 10 n n 10 k x 1.1. a 1, a 2,, a n, (a n ) n=1 {a n } n=1 1.2 ( ). {a n } n=1 Q ε > 0 N N m, n N a m
![n 2 + π2 6 x [10 n x] x = lim n 10 n n 10 k x 1.1. a 1, a 2,, a n, (a n ) n=1 {a n } n=1 1.2 ( ). {a n } n=1 Q ε > 0 N N m, n N a m](/thumbs/94/118912662.jpg "n 2 + π2 6 x [10 n x] x = lim n 10 n n 10 k x 1.1. a 1, a 2,, a n, (a n ) n=1 {a n } n=1 1.2 ( ). {a n } n=1 Q ε > 0 N N m, n N a m")
1 1 1 + 1 4 + + 1 n 2 + π2 6 x [10 n x] x = lim n 10 n n 10 k x 1.1. a 1, a 2,, a n, (a n ) n=1 {a n } n=1 1.2 ( ). {a n } n=1 Q ε > 0 N N m, n N a m a n < ε 1 1. ε = 10 1 N m, n N a m a n < ε = 10 1 N
MultiWriter 5600C 活用マニュアル
1 *1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 8 9 9 1 2 3 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 1 2 3 a b c 26 27 28 C *1 *2 *2 29 2 2 2 2 2 2 2 2 2 30 *1 *2 ± *1 C C 31 32 33 34 35 36 M C Y K 1 2 3 4 5 6
untitled
I...1 II...2...2 III...3...3...7 IV...15...15...20 V...23...23...24...25 VI...31...31...32...33...40...47 VII...62...62...67 VIII...70 1 2 3 4 m 3 m 3 m 3 m 3 m 3 m 3 5 6 () 17 18 7 () 17 () 17 8 9 ()
TOTAL INCOME Part B - TI (Schedule-HP) (nil ) 2 0 2 i 2i 0 (Schedule-BP) () ii 2ii 0 (Schedule BP) (schedule CFL) iii 2iii 0 (Schedule BP) ( ) iv Tota
ITR-6 S. ] 2 0 4-5 Corporate Identity Number (CIN) Email Email - 2 Income Tax Ward/Circle Receipt No Notice No ( (DD/MM/YYYY) 00/00/0000 (Std ) ection? Pin 94A? a b c ection 44AA ection 44AB 44AB? a (DD/MM/YYYY)
01_.g.r..
I II III IV V VI VII VIII IX X XI I II III IV V I I I II II II I I YS-1 I YS-2 I YS-3 I YS-4 I YS-5 I YS-6 I YS-7 II II YS-1 II YS-2 II YS-3 II YS-4 II YS-5 II YS-6 II YS-7 III III YS-1 III YS-2
AD-5423_2
/ 2 /2.7 /CTD 8 8 II II 1 2 6 mg/ 6 mg/ HIV C 80 mmhg 3 1 3 80 mmhg 31 / 2 /2.7 /CTD 8 8 II II 1 2 3 23 32 / 2 /2.7 /CTD 2.7.3.3.1-28 123 2.7.3.3.1-2 8 1 2 3 2.7.3.3.1-3 2.7.3.3.1-48 2.7.3.3.1-5 40 5 7
Agilent 7900 ICP-MS 1 1 Ed McCurdy 2 1 Agilent Technologies, Japan 2 Agilent Technologies, UK
Agilent 7900 ICP-MS 1 1 Ed McCurdy 2 1 Agilent Technologies, Japan 2 Agilent Technologies, UK Na P K Ca Co Cu Sr Cd Ce Cs Tl 11 [1]18 [2] (FAO) (WTO) (Codex) Pb Cd As Sn Pb 0.3 mg/kg Cd 0.4 mg/kg 0.2 mg/kg
CuSO POINT S 2 Ni Sn Hg Cu Ag Zn 2 Cu Cu Cu OH 2 Cu NH CuSO 4 5H 2O Ag Ag 2O Ag 2CrO4 Zn ZnS ZnO 2+ Fe Fe OH 2 Fe 3+ Fe OH 3 2 Cu Cu OH 2 Ag Ag
CuSO POINT S 2 Ni Sn Hg Cu Ag Zn 2 CuCu Cu OH 2 Cu NH 3 4 2 CuSO 4 5H 2O AgAg 2O Ag 2CrO4 ZnZnS ZnO 2+ Fe Fe OH 2 Fe 3+ Fe OH 3 2 Cu Cu OH 2 Ag Ag 2O Cl Cl AgCl PbCl 2 Ag Cl AgCl Pb 2 2Cl PbCl2 Cl Hg22
活用ガイド （ソフトウェア編）
(Windows 95 ) ii iii iv NEC Corporation 1999 v P A R T 1 vi P A R T 2 vii P A R T 3 P A R T 4 viii P A R T 5 ix x P A R T 1 2 3 1 1 2 4 1 2 3 4 5 1 1 2 3 4 6 5 6 7 7 1 1 2 8 1 9 1 1 2 3 4 5 6 1 2 3 4
-2-
-1- -2- -3- 1 2 Pseudomonas avenae 34 36 3 25 20 4 1 200 300 2 18 20 5 24 10 ml 20 12 24 3-4- 4 32 33 3 1 60 30 3cm 1 2 1 3 1 3 2 3 1 2 1 1 3 2 2 1 300 3 1 5 0 1 1 2 2 3 3 4-5- 1nl 2n2 3n3 4n4 4N 100 N
α β *2 α α β β α = α 1 β = 1 β 2.2 α 0 β *3 2.3 * *2 *3 *4 (µ A ) (µ P ) (µ A > µ P ) 10 (µ A = µ P + 10) 15 (µ A = µ P +
Armitage 1 1.1 2 t *1 α β 1.2 µ x µ 2 2 2 α β 2.1 1 α β α ( ) β *1 t t 1 α β *2 α α β β α = α 1 β = 1 β 2.2 α 0 β 1 0 0 1 1 5 2.5 *3 2.3 *4 3 3.1 1 1 1 *2 *3 *4 (µ A ) (µ P ) (µ A > µ P ) 10 (µ A = µ P
3 5 18 3 5000 1 2 7 8 120 1 9 1954 29 18 12 30 700 4km 1.5 100 50 6 13 5 99 93 34 17 2 2002 04 14 16 6000 12 57 60 1986 55 3 3 3 500 350 4 5 250 18 19 1590 1591 250 100 500 20 800 20 55 3 3 3 18 19 1590
名称未設定-2
Contents 1 2 3 4 5 6 7 8 9 1 11 12 13 14 15 16 17 18 19 2 21 22 i 23 24 25 26 27 28 29 3 31 32 33 34 35 36 37 38 39 4 41 42 43 44 45 46 47 48 49 5 51 52 53 54 55 56 57 ii 58 59 6 61 62 63 64 65 66 67 68
困ったときのQ&A
ii iii iv NEC Corporation 1997 v P A R T 1 vi vii P A R T 2 viii P A R T 3 ix x xi 1P A R T 2 1 3 4 1 5 6 1 7 8 1 9 1 2 3 4 10 1 11 12 1 13 14 1 1 2 15 16 1 2 1 1 2 3 4 5 17 18 1 2 3 1 19 20 1 21 22 1
IFRS連結財務諸表記載例2013年版-3
付録 1- 連結包括利益計算書 (1 計算書方式の事例 ) IAS 1.10(b) 2012 年 12 月 31 日に終了する事業年度 IAS 1.51(b)(c) 注釈当グループは 損益計算書を 2 計算書方式により表示している この付録では 1 計算書方式による包括利益計算書を例示している IAS 1.10(b) IAS 1.51(b)(c) 2012 年 2011 年 修正再表示後 * IAS
10-7 cm/ 50cm 10-6 cm/ 2,4-D 2 ph
10-7 cm/ 50cm 10-6 cm/ 2,4-D 2 ph Cd 2+ Ca 2+ - Cr(OH) 4 ph ph ph ph 6 CrO 2-4 AsO 3-4 ph 9 Cd 2+ ph 6 ph 9 ph 6 9 ph B(OH) - 4 ph B(OH) 3 ph ph B(OH) - 4 ph soil organic matter ph ph ph ph 2,4-D ph 2,4-D
2 1 7 - TALK ABOUT 21 μ TALK ABOUT 21 Ag As Se 2. 2. 2. Ag As Se 1 2 3 4 5 6 7 8 9 1 1 2 3 4 5 6 7 8 9 1 1 2 3 4 5 6 7 8 9 1 Sb Ga Te 2. Sb 2. Ga 2. Te 1 2 3 4 5 6 7 8 9 1 1 2 3 4 5 6 7 8 9 1 1 2 3 4
248 Nippon Shokuhin Kagaku Kogaku Kaishi Vol. /-, No./,,.2,/. (,**0) 12 * * * Microencapsulation of Glutamine with Zein by a Solvent Evaporation Metho
248 Nippon Shokuhin Kagaku Kogaku Kaishi Vol. /-, No./,,.2,/. (,**0) 12 * * * Microencapsulation of Glutamine with Zein by a Solvent Evaporation Method in Reverse Multiple Emulsion Masato Tanaka*, Yoshinari
[ ] (Verschieden Wissenschaft auf Pedologie fur Geologe) (Taqumi, TuZino) Julius 2007 I. 3 II. 3 II. 1 : : : : : : : : : : : : :
![[ ] (Verschieden Wissenschaft auf Pedologie fur Geologe) (Taqumi, TuZino) Julius 2007 I. 3 II. 3 II. 1 : : : : : : : : : : : : :](/thumbs/99/141558843.jpg "[ ] (Verschieden Wissenschaft auf Pedologie fur Geologe) (Taqumi, TuZino) Julius 2007 I. 3 II. 3 II. 1 : : : : : : : : : : : : :")
[ ] (Verschieden Wissenschaft auf Pedologie fur Geologe) 2008 1 8 (Taqumi, TuZino) 2008 1 8 10 Julius 2007 I. 3 II. 3 II. 1 : : : : : : : : : : : : : : : : : : : : : : : : : : : : 3 II. 2 : : : : : : :
CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation
CHEMOTHERAPY CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation CHEMOTHERAPY Table 1 Preliminaly test of AM- 715 1): Mean } SD *: Significant difference
untitled
1998 6 25 ( ) 1 10 1982 10 28 37/7 1990 12 14 45/94 (WHO) 1 1989 12 8 NGO (ECE) 3 1995 10 25 ECE 1991 2 25 1992 3 17 1998 6 4 1 2 1. 2. a b c (a) (b) d 17 3. a b (a) c (b) 4. 5. 3 1. 2. 3. 4. 5. 6. 7.
